In summary, we have validated that KMT2A modifies the H3K4me3 on the PU.1 gene promoter region, and treatment with KMT2A inhibitor can alleviate bleomycin‐induced pulmonary fibrosis in mice, indicating the potential of KMT2A to be therapeutic target. The gene discussed is KMT2A; the disease is pulmonary fibrosis.